|
|
 Previous Article | Table of Contents | Next Article 
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody
to CD20
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna and DR Anderson
IDEC Pharmaceuticals Corporation, San Diego, CA 92121.
Murine monoclonal antibody 2B8 specifically recognizes the CD20
phosphoprotein expressed on the surface of normal B lymphocytes and B- cell
lymphomas. The light- and heavy-chain variable regions of 2B8 were cloned,
after amplification by the polymerase chain reaction, into a cDNA
expression vector that contained human IgG1 heavy chain and human
kappa-light chain constant regions. High-level expression of chimeric- 2B8
antibody (C2B8) was obtained in Chinese hamster ovary cells. Purified C2B8
exhibited antigen binding affinity and human-tissue reactivity similar to
the native murine antibody. In vitro studies showed the ability of C2B8 to
bind human C1q, mediate complement- dependent cell lysis of human
B-lymphoid cell lines, and lyse human target cells through
antibody-dependent cellular cytotoxicity. Infusion of macaque cynomolgus
monkeys with doses ranging from 1.6 mg/kg to 6.4 mg/kg resulted in greater
than 98% depletion of peripheral blood (PB) B cells and 40% to 70%
depletion of lymph node B cells. Recovery of PB B cells usually started at
2 weeks after treatment and required 60 to greater than 90 days to reach
normal levels. As much as 95% depletion of B cells in peripheral lymph
nodes and bone marrow was observed following weekly injections of 16.8
mg/kg antibody. No toxicity was observed in any of the animals. These
results offer the possibility of using an "immunologically active" chimeric
anti-CD20 antibody as an alternative approach in the treatment of B-cell
lymphoma.
Volume 83,
Issue 2,
pp. 435-445,
01/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. A Heemstra, R. E Toes, J. Sepers, A. M Pereira, E. P Corssmit, T. W J Huizinga, J. A Romijn, and J. W Smit
Rituximab in relapsing Graves' disease, a phase II study
Eur. J. Endocrinol.,
November 1, 2008;
159(5):
609 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4587 - 4594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Mattes, R. M. Sharkey, H. Karacay, M. S. Czuczman, and D. M. Goldenberg
Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
Clin. Cancer Res.,
October 1, 2008;
14(19):
6154 - 6160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C B Driver, M Ishimori, and M H Weisman
The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Ann Rheum Dis,
October 1, 2008;
67(10):
1374 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood,
September 15, 2008;
112(6):
2261 - 2271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Ferraro, S. W. Smith, D. Neil, and C. O.S. Savage
Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood
Nephrol. Dial. Transplant.,
September 1, 2008;
23(9):
3030 - 3032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Beum, M. A. Lindorfer, and R. P. Taylor
Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
J. Immunol.,
August 15, 2008;
181(4):
2916 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV
Blood,
August 15, 2008;
112(4):
1205 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Ruckert, H Glimm, M Lubbert, and C Grullich
Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up
Lupus,
August 1, 2008;
17(8):
757 - 760.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, O. W. Press, S. M. Wilbur, D. G. Maloney, and J. M. Pagel
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
Blood,
August 1, 2008;
112(3):
830 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Vo, M. Lukovsky, M. Toyoda, J. Wang, N. L. Reinsmoen, C.-H. Lai, A. Peng, R. Villicana, and S. C. Jordan
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
N. Engl. J. Med.,
July 17, 2008;
359(3):
242 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shimada, K. Matsue, K. Yamamoto, T. Murase, N. Ichikawa, M. Okamoto, N. Niitsu, H. Kosugi, N. Tsukamoto, H. Miwa, et al.
Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan
J. Clin. Oncol.,
July 1, 2008;
26(19):
3189 - 3195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor
Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
J. Immunol.,
July 1, 2008;
181(1):
822 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi
Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
J. Clin. Oncol.,
June 1, 2008;
26(16):
2725 - 2731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kondo, T. Tanaka, T. Miyake, T. Ichikawa, M. Hirai, M. Adachi, K. Yoshikawa, K. Ichimura, N. Ohara, A. Moriwaki, et al.
Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines
Mol. Cancer Ther.,
June 1, 2008;
7(6):
1461 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, C. Su, Q. Lu, W. Shi, Q. Zhang, X. Wang, J. Long, Q. Yang, L. Li, X. Jia, et al.
Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey
Mol. Cancer Ther.,
June 1, 2008;
7(6):
1562 - 1568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kurosawa, Y. Akahori, M. Morita, M. Sumitomo, N. Sato, C. Muramatsu, K. Eguchi, K. Matsuda, A. Takasaki, M. Tanaka, et al.
Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic
PNAS,
May 20, 2008;
105(20):
7287 - 7292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al.
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Cancer Res.,
May 15, 2008;
68(10):
3863 - 3872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Isenberg
Treating patients with lupus with B-cell depletion
Lupus,
May 1, 2008;
17(5):
400 - 404.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. E. Fassi, C. H Nielsen, J. Kjeldsen, O. Clemmensen, and L. Hegedus
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
Gut,
May 1, 2008;
57(5):
714 - 715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baba, M. Okamoto, T. Hamasaki, S. Horai, X. Wang, Y. Ito, Y. Suda, and N. Arima
Highly Enhanced Expression of CD70 on Human T-Lymphotropic Virus Type 1-Carrying T-Cell Lines and Adult T-Cell Leukemia Cells
J. Virol.,
April 15, 2008;
82(8):
3843 - 3852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Li, S. Shi, W. Qian, L. Zhao, D. Zhang, S. Hou, L. Zheng, J. Dai, J. Zhao, H. Wang, et al.
Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity
Cancer Res.,
April 1, 2008;
68(7):
2400 - 2408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kapadia, J. M. Engles, and R. L. Wahl
In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab
J. Nucl. Med.,
April 1, 2008;
49(4):
674 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al.
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
N. Engl. J. Med.,
February 14, 2008;
358(7):
676 - 688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. I. Pathan, P. Chu, K. Hariharan, C. Cheney, A. Molina, and J. Byrd
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
Blood,
February 1, 2008;
111(3):
1594 - 1602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bremer, B. ten Cate, D. F. Samplonius, N. Mueller, H. Wajant, A. J. Stel, M. Chamuleau, A. A. van de Loosdrecht, J. Stieglmaier, G. H. Fey, et al.
Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
Cancer Res.,
January 15, 2008;
68(2):
597 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose
Maintenance Rituximab-Should It Be Given to Every Patient with Follicular Lymphoma?
ASCO Educational Book,
January 1, 2008;
2008(1):
386 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Berentsen
Rituximab for the treatment of autoimmune cytopenias
Haematologica,
December 1, 2007;
92(12):
1589 - 1596.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco
In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab
Cancer Res.,
November 1, 2007;
67(21):
10556 - 10563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Stavenhagen, S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Johnson, E. Bonvini, and S. Koenig
Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors
Cancer Res.,
September 15, 2007;
67(18):
8882 - 8890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol.,
September 15, 2007;
179(6):
4263 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ahuja, J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik
Depletion of B Cells in Murine Lupus: Efficacy and Resistance
J. Immunol.,
September 1, 2007;
179(5):
3351 - 3361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T M El-Shanawany, P E Williams, and S Jolles
Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab
J. Clin. Pathol.,
June 1, 2007;
60(6):
715 - 716.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al.
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
J. Clin. Oncol.,
May 20, 2007;
25(15):
1986 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
J. Biol. Chem.,
May 18, 2007;
282(20):
15073 - 15080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn
Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab
Clin. Cancer Res.,
April 15, 2007;
13(8):
2392 - 2399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nomura, K. Ishii, Y. Kamitsuji, N. Uoshima, E. Ishikawa, H. Kitayama, and K. Hayashi
Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2007;
13(2):
206 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al.
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Ann Rheum Dis,
April 1, 2007;
66(4):
470 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al.
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Cancer Res.,
March 15, 2007;
67(6):
2872 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kurai, H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, T. Sako, H. Touge, H. Makino, M. Takata, M. Miyata, et al.
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Clin. Cancer Res.,
March 1, 2007;
13(5):
1552 - 1561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, and B. Bonavida
Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy
Cancer Res.,
February 1, 2007;
67(3):
1270 - 1281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Wong
Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?
Nephrol. Dial. Transplant.,
January 1, 2007;
22(1):
32 - 36.
[Full Text]
[PDF]
|
|
|
|
